VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+8.21%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$214M
AUM Growth
+$9.71M
(+4.8%)
Cap. Flow
+$1.5M
Cap. Flow
% of AUM
0.7%
Top 10 Holdings %
Top 10 Hldgs %
6.68%
Holding
490
New
42
Increased
186
Reduced
165
Closed
36
Top Buys
| 1 |
OCCI
OFS Credit Co
OCCI
|
$2.06M |
| 2 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
$1.96M |
| 3 |
Applovin
APP
|
$1.49M |
| 4 |
Constellation Energy
CEG
|
$1.32M |
| 5 |
ECC
Eagle Point Credit Co
ECC
|
$1.26M |
Top Sells
| 1 |
OXLC
Oxford Lane Capital
OXLC
|
$1.49M |
| 2 |
Gen Digital
GEN
|
$1.01M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
$1M |
| 4 |
Adobe
ADBE
|
$989K |
| 5 |
Steris
STE
|
$907K |
Sector Composition
| 1 | Financials | 28.16% |
| 2 | Healthcare | 18.37% |
| 3 | Technology | 14.33% |
| 4 | Industrials | 8.16% |
| 5 | Consumer Discretionary | 6.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CRGX
376
DELISTED
CARGO Therapeutics
CRGX
| $99K | 0.05% |
5,368
+99
| +2% | +$1.83K |
|
377
Janux Therapeutics
JANX
$1.44B
| $98.9K | 0.05% |
2,178
+41
| +2% | +$1.86K |
|
378
Immunovant
IMVT
$2.99B
| $98.7K | 0.05% |
3,462
+59
| +2% | +$1.68K |
|
379
Dyne Therapeutics
DYN
$2.02B
| $98.3K | 0.05% |
2,736
+49
| +2% | +$1.76K |
|
380
Terns Pharmaceuticals
TERN
$632M
| $96.3K | 0.05% |
11,550
+206
| +2% | +$1.72K |
|
381
Savara
SVRA
$643M
| $96.3K | 0.05% |
22,701
+404
| +2% | +$1.71K |
|
382
Xenon Pharmaceuticals
XENE
$3.02B
| $95.5K | 0.04% |
2,425
+45
| +2% | +$1.77K |
|
|
EXAI
383
DELISTED
Exscientia Plc American Depositary Shares
EXAI
| $94.5K | 0.04% |
19,359
+341
| +2% | +$1.66K |
|
384
Pharvaris
PHVS
$1.48B
| $94.2K | 0.04% |
5,089
+88
| +2% | +$1.63K |
|
385
Dianthus Therapeutics
DNTH
$853M
| $93.7K | 0.04% |
3,422
+64
| +2% | +$1.75K |
|
386
Cytokinetics
CYTK
$6.34B
| $92.2K | 0.04% |
1,747
+30
| +2% | +$1.58K |
|
387
Neurogene
NGNE
$285M
| $92.1K | 0.04% |
2,194
+38
| +2% | +$1.59K |
|
388
Arcutis Biotherapeutics
ARQT
$2.06B
| $91.8K | 0.04% |
9,867
+175
| +2% | +$1.63K |
|
389
Annexon
ANNX
$238M
| $90.8K | 0.04% |
15,339
+276
| +2% | +$1.63K |
|
390
Celcuity
CELC
$2.36B
| $89.5K | 0.04% |
6,006
+105
| +2% | +$1.57K |
|
391
Beam Therapeutics
BEAM
$2.11B
| $89.5K | 0.04% |
3,653
+66
| +2% | +$1.62K |
|
392
Olema Pharmaceuticals
OLMA
$570M
| $88.3K | 0.04% |
7,394
+129
| +2% | +$1.54K |
|
393
Mineralys Therapeutics
MLYS
$2.31B
| $88K | 0.04% |
7,267
+133
| +2% | +$1.61K |
|
394
Alector
ALEC
$305M
| $87.1K | 0.04% |
18,697
+335
| +2% | +$1.56K |
|
395
Xencor
XNCR
$610M
| $86.9K | 0.04% |
4,323
+75
| +2% | +$1.51K |
|
396
uniQure
QURE
$985M
| $86.6K | 0.04% |
17,556
+313
| +2% | +$1.54K |
|
|
BLTE
397
Belite Bio
BLTE
$2.16B
| $86.4K | 0.04% |
1,843
+36
| +2% | +$1.69K |
|
398
Pliant Therapeutics
PLRX
$114M
| $86.3K | 0.04% |
7,697
+134
| +2% | +$1.5K |
|
399
Celldex Therapeutics
CLDX
$1.52B
| $86K | 0.04% |
2,529
+44
| +2% | +$1.5K |
|
400
Arvinas
ARVN
$575M
| $85.9K | 0.04% |
3,486
+63
| +2% | +$1.55K |
|